

The Study of Magnesium Sulphate Vs Diazepam in Eclampsia

Tariq Masood Khan



The Study of Magnesium Sulphate Vs Diazepam in Eclampsia

By

Dr. Tariq Masood Khan (MCPS, MCPS, FM, DCPS, OBG)

Family / Emergency Medicine Specialist / Internist

Student Ms Obs/Gyn

Obstetrics and Gynaecology Department

Lady Willingdon Hospital Lahore

Prof. Dr. Aisha Malik

Fcps (Pak) Mrcog (Uk)

Professor of Obstetrics and Gynaecology

King Edward Medical College Lahore

Visiting Surgeon Lady Willingdon Hospital Lahore

Published By:

MedCrave Group

Published Date: July 18, 2016



Acknowledgement

In The Name Of Allah the Most Gracious, The Most Merciful, Whose Compassion And Blessings Are Always Yearned By Me

I acknowledge the guidance and affective, supervision of professor Ahmed Wasim Yousaf Professor of obstetrics and Gynecology King Edward Medical College and Lady Willingdon Hospital Lahore whose personal sincerity with work / guidance / devotion persuaded me to do my best, and with out his guidance and supervision it would not have been possible to complete it.

I owe debt to professor Dr. Ayesha Malik, Also Prof. Dr. Uzma Asstt. Professor Obstetrics and Gynecology, Dr. Mamoonah King Edward Medical College for constructive criticism and always kind assistance.

I am thankful to the staff of Lady Willingdon Hospital Kind Edward Medical College Lahore for their cooperation in obtaining relevant reference and concerned material. All my friends and family members, especially my wife deserve thanks for encouraging and supporting me and always thanks Pray, Praise God Almighty.

Lastly I am thankful to Mr. Akmal / Saeed / Kashif for composing the main script.

May Allah bless them all.

Abstract

Eclampsia is a life threatening condition with highest mortality and morbidity characterized by uncontrolled hypertension un-consciousness fits albumin urea in the setting the of Pre Eclampsia.

Study: An extensive elaborative study carried out from 2005 to 2009, to study the therapeutic and prophylactic role of Magnesium Sulphate and Diazepam in Eclampsia.

Study Period: Four Years 2005 to 2009.

Objective: To study MgSO₄ Vs Diazepam reducing MMR, NMR in Eclampsia.

Study Design: This was a comparative study. Total 500 patients of fulminant pre- Eclampsia / Eclampsia were studied included booked / un-booked patients attending Lady Willingdon Hospital were admitted evaluated assessed and put on MgSO₄ Vs Diazepam divided in two groups. The results were compared which showed of MgSO₄ as superior in efficacy of compared to Diazepam in improving overall mortality morbidity in Eclampsia.


Material and Methods: Total 500 patients of Eclampsia admitted and studied in Unit – 2 Lady Willingdon Teaching Hospital of King Edward Medical University Lahore managed in ICU according to a specially design proforma, protocol and were given MgSO₄ and Diazepam for control of fits, Hydralazine, Labetalol and Isoket infusions for lowering – blood pressure (MgSO₄) A+B. (Diazepam) with multi disciplinary involvement divided in two groups compared and followed up.

Results: In Group-A there were 20 mothers and in Group-B 40 mothers died. It was observed that maternal mortality was significantly higher in Group-B women as compared to that of Group-A. i.e. (p-value=0.005) In Group-A there were 20 mothers and in Group-B 40 mothers died. It was observed that maternal mortality was significantly higher in Group-B women as compared to that of Group-A. i.e. (p-value=0.005)

Conclusion: The comparative study and of role of MgSO₄ Vs Diazepam in reducing Mortality, morbidity in maternities, neoneties, efficacy showed the superiority of Magnesium Sulphate as compared to Diazepam without any doubt.

Keywords: Therapeutic; Prophylactic role; Magnesium Sulphate; Diazepam; Eclampsia

List of Abbreviations



APH	Antepatum Hemorrhage
CM	Centimeter
D & C	Dilation and Curettage
D/W	Dextrose Water
DI	Deciliter
ESR	Erythrocyte Sedimentation Rate
EUA	Examination under Anesthesia
HB	Hemoglobin
I/M	Intramuscular
I/V	Intravenous
INJ	Injection
EDD	Expected Date Of Delivery
LMP	Last Menstrual Period
LBG	Last Born Child
MG	Milligram
NO	Number
DIC	Disseminated Intravascular Coagulation
PPN	Post Partum Hemorrhage
TEMP	Temperature
BP	Blood Pressure
ATD	After Test Dose
PIH	Pregnancy Induced Hypertension
PET	Pre Eclamptic Toxemia
MgSO ₄	Magnesium Sulphate
CVA	Cerebro – Vascular Accidents
IUD	Intra – Uterine Death
IUGR	Intra Uterine, Growths Restrictions
MMR	Maternal Mortality Rate
NMR	Neonatal Mortality Rate

Contents

Introduction	1
Maternal Immunology	2
The Maternal Debus Theory	3
Review of Literature	4
Time of Onset of Eclampsia	5
Maternal-Perinatal Complications	6
Evaluation	8
The Use of Magnesium Sulphate for the Treatment of Eclampsia the Magpie Trial	11
Mechanism of Action	12
Availability of MgSO ₄	13
MgSO ₄ regimens	14
Clinical Detection of Toxicity	15
Training on MgSO ₄	16
Objective	17
Material & Methods	18
Data Analysis	20
Results	21
Discussion	23
Conclusion	24
Guidelines for the immediate management of ECLAMPSIA and IMMINENT ECLAMPSIA	
Examine Apatient of Pih / Pet Pregnancy Induced Hypertension Pre-Eclamptic	
Examine a Patient of Hypertension and gestational Diabetes: Pih + Gdm	
Guide Lines/Key Points Symptomatology/Management Protocol Pre Eclampsia Eclampsia	
Recommendations for Management	30
Pre Eclampsia/Eclampsia-Dic	31
Key Points – MgSO ₄ Vs Diazepam	32
References	33

Introduction

Eclampsia is defined as the onset of convulsions seizures activity during pregnancy or post partum in a patient who have signs and symptoms of Fulminant Pre-eclampsia eclampsia i.e. hypertension & albuminuria mostly after the 20th week of Pregnancy. Eclampsia is a life threatening emergency that continues to be a major cause of serious maternal neonatal morbidity and mortality worldwide. In developing countries eclampsia accounts for about one third of maternal deaths. Complicated cases and mismanaged cases are responsible for most maternal deaths which are usually due to cerebrovascular accidents, pulmonary oedema, renal hepatic, or respiratory failure, or multi system failure, DIC, Hypertensive encephalopathy/Aspiration, Mendleson Aspiration Syndrome. Pulmonary Embolism etc.

In addition it is associated with high perinatal mortality and neonatal morbidity. The pathophysiology of eclamptic seizures is not understood. The main causes of perinatal mortality and neonatal morbidity from Eclampsia are pre-term delivery, fetal growth retardation and abruption placenta. Fetal distress, pre-maturity, Asphyxia, Neonatorum. Our objective of study was to study Magnesium Sulphate Vs Diazepam in reducing mother and child mortality in Pre-Eclampsia and Eclampsia. Urgent interventions are required to manage patients / and increase public awareness, the need for case referral and to raise the level of understanding, improving attitudes and practice in relation to Eclampsia. Pre-eclampsia / Eclampsia has been recognized as a clinical entity since the time of Hippocrates. In 1916 Zweifel first termed "toxemia the disease of theories".

Many of the theories attributed to pre-eclampsia/eclampsia describe pathological features of clinical presentation which are the result rather than the cause of the disease process. It has been thought to be a neurological, renal, hepatic, hypertensive and more recently a placental disorder. It is the result of both pathological change and maternal response. In different women, the rate of progression and the organ systems affected can be different. There needs to be an initial placental trigger but it is the maternal response that probably modifies the disease presentation and progression. By trying to understand the variations of disease presentation and progression, management of the affected women can become clearer and outcomes are predictable. One thing, that is agreed by all, is that placenta is required for the development and maintenance of pre-eclampsia/eclampsia and delivery, with removal of placenta-remains the ultimate cure and is evidenced based that the role of Magnesium Sulphate Vs Diazepam remains superior to Diazepam in both reducing maternal/neonatal morbidity/mortality. Evidence in support of the multiple modular approaches to pre-eclampsia includes.

I. Poor placenta ion

- a. Deficient trophoblast invasion
- b. Failure of adaptation of maternal vessels.

- c. Increased incidence of placental insufficiency.
- d. Hyperplacentosis
- e. Increased incidence in twin pregnancy
- f. Increased incidence in diabetics
- g. Increased incidence in rhesus incompatibility
- h. Association with molar pregnancy

II. Fetal/Placental Response

- a. Need for placenta to be present to develop the disease.
- b. Need for placenta to be present for continuation of disease.
- c. Abnormalities of villous formation.

III. Systemic reaction: Activation of circulating neutrophils

- a. Vcam-1 is elevated in the seizures
- b. Abnormalities of lymphocyte function
- c. Increased cytokine activity
- d. Increased lipid peroxide production.

IV. Maternal Response

- a. Decreased cellular protection for free radical activity
- b. Generalized membrane instability
- c. Diminished vascular endothelial function.

V. Increased vascular resistance / vasoconstriction

- a. Hypertension
- b. Renal impairment
- c. Convul

Diagram of components of the pathophysiology of pre-eclampsia/eclampsia that make up the multi system disorder. Pre-eclampsia/eclampsia only occurs in the presence of placenta. It usually but not always associated with placental insufficiency and intra uterine growth restriction IUGR. Hypertension in Pregnancy does not cause growth retardation but co-events with placental functions resulting in the restriction of growth. Both normal and abnormal implantation is likely to be influenced by maternal/fetal immunological interactions. Large granular Macrophages and lymphocytes, as they are important to mother's ability to recognize the invading trophoblast and respond appropriately to it. An abnormal or excessive maternal immunological response may lead to deficient implantation and poor placenta ion.

Maternal Immunology

Evidence for and against an immunological basis to pre-eclampsia.

- I. **For**
 - a. More common in primigravidae
 - b. More common in twin pregnancies
 - c. Incidence increased by change of partner.
 - d. A higher incidence of HLA homozygosity.
- II. **Against**
 - a. The increase in ABO, HLA, linked compatibility
 - b. The incidence in monozygotic/dizygotic reproductions.
 - c. Similar placental findings are found in IUGR

The “utero-placental ischemia is responsible for pre-eclampsia.” It is believed that placental ischemia results in the release of a substance “Factor X”. It is the maternal reaction to any placental factor that produces the signs & symptoms of pre-eclampsia.

The Maternal Debus Theory

The substance responsible for the systematic reaction may be pregnancy placental villi.

Maternal immunology

Immunocytes-clinical studies have localized neutrophil diastase in term placenta, decidua and myometrium in women with PET. The cell adhesion molecule V-cam is elevated in peripheral circulation. TNFX has been shown to be increased in PET.

- a. Abnormalities in various cell types could explain the immunological activity red cell fragility, platelet activation, hepatocyte dysfunctions, glomerular endotheliosis and neuronal sensitivity. Therefore all the clinical manifestations of pre-eclampsia can be explained by cellular dysfunction secondary to response to circulating factors in maternal blood.
- b. Alterations in the membrane of the red cell can alter blood physiology and tendency to lyse and can explain many of the clinical findings in this condition.
- c. The red cell in women with pre-eclampsia is deficient in intracellular free radical scavengers, opening them to increased damage and membrane instability. Levels of antioxidant activity correlate with plasma levels of prostacyclin and thromboxanes are common with pregnancy induced hypertension. These changes particularly those found with superoxide dismutase (SOD) have been found in neutrophils. This decreased SOD activity would appear to be a secondary phenomenon.
- d. The most common physical presentation of the eclampsia is hypertension. Vascular endothelial cell dysfunctions is certainly part of the disease process, though not permanent endothelial damage.

Hereditary factors

Multiple studies have suggested that pre-eclampsia

is a familial disease. It seems likely that there may be genetic factors that modulate the process, the so called MODULATOR GENES. Recent studies confirmed this family linkage and results are consistent with single gene dominance with 48% inheritance.

- i. Gene linkage with in Family groups is being investigated
- ii. Angio Tensinogen: a candidate gene involved in pre-eclampsia.

Arrngrusson et al. in a study of several generations of women found evidence for role of AGT on neighbouring gene in predisposition to pre-eclampsia. This was true for women with both Proteinuric and non pre-Proteinuric and especially with Proteinuric hypertension having increased significant level.

- iii. This suggests that genetic factor may be related to hypertension of PET and risk of convulsions is related to another, may be genetic cause.

TNF & Gene in pre-eclampsia

TNF can affect cells in many ways including (1) altering the balance between oxidant and antioxidant.

MgSO₄ VS Diazepam

Though MgSO₄ is the drug of choice for fulminant pre-eclampsia and eclampsia, with a very narrow range of safety margins, monitoring of drug levels is mandatory, with the 3R Parameters, Renal output more than 30ml/hr, diminished/respiratory rate less than 12/min, then reduce or stop altogether Reduce or absent reflex activity 0.5gm/hr. 1-2 gm /hr is the maintenance dose MgSO₄ is given as Propylactic and therapeutic dose, Diazepam the drug, is given very slowly, as it can depress respiratory rate, MgSO₄ 52% better than Diazepam and 67% than phenothiazine. The level of MgSO₄ is in maintenance 4-7 in Eq / lit, as there is narrow therapeutic range, so MgSO₄ level be monitored critically.

Review of Literature

Historical background

Despite lack of complete understanding, preeclampsia and eclampsia have been recognized and described many centuries ago. Hippocrates observed that headaches, convulsions, fits and drowsiness are ominous signs in association with pregnancy. In his treatise on gynecology varandeeus coined the term eclampsia in 1619. Evidence exist that ancient civilization of China, Egypt and India have all recognized and narrated this disease as well as the bleak maternal and fetal prognosis it has Association with hypertension and proteinuria, the two cardinal features were noted in mid to late 19th century (hypertension) and the early 20th century proteinuria. Delivery was further identified as the key and salient feature of management in the 20th century. Notwithstanding the extensive literature and progress in our understanding, these facts still remains the basis of our management of preeclampsia and eclampsia [1,2].

Epidemiology

Eclampsia is defined as the onset of seizures / fits in the setting of preeclampsia and without another neurologic or medical causes or condition. The spectrum of hypertensive disease in pregnancy, which includes preeclampsia-eclampsia, is one of the leading causes of maternal morbidity and mortality both in the United States and worldwide, resulting in 10-15% of maternal deaths [3-5]. Eclampsia is further associated with increased morbidity due to risks of hypoxic-ischemic brain damage and intracranial hemorrhage from seizure activity [6]. Of eclampsia cases, 2-20% are complicated by perinatal loss, while 1-20% are complicated by maternal fatality, with the highest rates of morbidity and mortality in developing countries [5,7,8]. The risk of eclamptic seizures is approximately 2% in patients with untreated severe preeclampsia, while it is roughly 0.5% in patients with mild preeclampsia [9]. Eclampsia may occur antenatally, intrapartum, or postnatally. The incidence of eclampsia is cited to be on the order of 2-8 cases per 10,000 deliveries in developed countries and up to 16-69 cases per 10,000 in developing countries. Several recent studies from Canada and Ireland have demonstrated a decline in eclampsia incidence over time [7,10]. Liu et al. [7] found a decline from 12.4 per 10,000 to 5.9 from 2003 through 2009 in Canada, while O'Connor et al. [5] found a decline from 5.4 per 10,000 to 3.5 over a span of 30 years in Ireland. It is believed that the use of magnesium sulfate prophylactically has been associated with a decrease in incidence of eclampsia [5,7,10,11].

Etiologic and risk factors for eclampsia

Genetic predisposition, immunology, endocrinology, nutrition, abnormal trophoblastic invasion, coagulation abnormalities, vascular endothelial damage, cardiovascular maladaptation, dietary deficiencies or excess, and infection have been proposed as etiologic factors for preeclampsia/eclampsia. Imbalanced prostanoid production and increased

plasma antiphospholipids have also been implicated in eclampsia [1,12,13].

Risk factors for eclampsia

- I. The following are considered risk factors for eclampsia
 - a. Nulliparity
 - b. Family history of preeclampsia, previous preeclampsia and eclampsia [13]
 - c. Poor outcome of previous pregnancy, including intrauterine growth retardation, abruptio placentae, or fetal death
 - d. Multifetal gestations, hydatid mole, fetal hydrops, primigravida
 - e. Teen pregnancy
 - f. Primigravida
 - g. Patient older than 35 years
 - h. Lower socioeconomic status
- II. The following preexisting medical conditions are also considered risk factors [1,14]:
 - i. Obesity
 - ii. Chronic hypertension
 - iii. Renal disease
 - iv. Thrombophilias-antiphospholipid antibody syndrome
 - v. Protein C deficiency and protein S deficiency
 - vi. Antithrombin deficiency
 - vii. Vascular and connective tissue disorders
 - viii. Gestational diabetes
 - ix. Systemic lupus erythematosus [14].

Pathophysiology of Eclampsia

Inhibition of uterovascular development: Many uterovascular changes occur when a woman is pregnant. It is believed that these changes are due to the interaction between fetal and maternal allograft and result in systemic and local vascular changes. It has been shown that in patients with eclampsia, the development of uteroplacental arteries is hindered [1].

Hindrance of cerebral blood flow regulation: It is believed that in eclampsia there is abnormal cerebral blood flow in the setting of extreme hypertension. The regulation of cerebral perfusion is inhibited, vessels become dilated with increased permeability, and cerebral edema occurs, resulting in ischemia and encephalopathy. In extreme hypertension, normal compensatory vasoconstriction may become defective. Several autopsy findings support this model and consistently reveal swelling and fibrinoid necrosis of vessel walls [1,13].

Endothelial dysfunction: Factors associated with endothelial dysfunction have been shown to be increased in the systemic circulation of women suffering from eclampsia. These include the following [1]:

- i. Cellular fibronectin
- ii. Von Willebrand factor
- iii. Cell adhesion molecules (ie, P-selectin, vascular endothelial adhesion molecule-1 [VCAM-1])
- iv. Intercellular adhesion molecule-1 [ICAM-1])
- v. Cytokines (ie, interleukin-6 [IL-6])
- vi. Tumor necrosis factor- α [TNF- α]

In addition, it is believed that antiangiogenic factors, such as placental protein fms-like tyrosine kinase 1 (sFlt-1) and activin A, antagonize vascular endothelial growth factor (VEGF) [7]. Elevated levels of these proteins cause a reduction of VEGF and induce systemic and local endothelial cell dysfunction [11]. Leakage of proteins

from the circulation and generalized edema are sequelae of the endothelial dysfunction and thus a defining factor associated with preeclampsia and eclampsia [1].

Oxidative stress: Evidence indicates that leptin molecules increase in the circulation of women with eclampsia, inducing oxidative stress, another factor in eclampsia, on cells [13,15]. (The leptin increase also results in platelet aggregation, most likely contributing to the coagulopathy associated with eclampsia.) Oxidative stress has been found to stimulate the production and secretion of the antiangiogenic factor activin A from placental and endothelial cells [16]. Studies in pregnant mouse models have proposed that there is a dysregulation in the reactive oxygen species (ROS) signaling pathway [15-17]. Studies also suggest that increased systemic leukocyte activity plays a role in the mediation of oxidative stress, inflammation, and endothelial cell dysfunction. Histochemistry studies indicate that there is predominantly an increase in neutrophil infiltration of vasculature in patients with eclampsia [1,17].

Time of Onset of Eclampsia

The onset of eclamptic convulsions can be antepartum, intrapartum, or postpartum. The reported frequency of antepartum convulsions among recent series has ranged from 38% to 53%. The frequency of postpartum eclampsia has ranged from 11% to 44%. Although most cases of postpartum eclampsia occur within the first 48 h, some cases can develop beyond 48 h postpartum and have been reported as late as 23 days postpartum [8,14,18-21]. The cases of eclampsia that occur after 48 h postpartum, but less than 4 weeks after delivery, are defined as late postpartum eclampsia. These women will have signs and symptoms consistent with preeclampsia in association with convulsions. Some of these women will demonstrate a clinical picture of preeclampsia during labor or immediately postpartum (56%), whereas others will demonstrate these clinical findings for the first time more than 48 h after delivery (44%) [19,21,22]. Of interest is the fact that late postpartum eclampsia developed despite the use of prophylactic magnesium during labor and for at least 24 h postpartum in previously diagnosed preeclampsia women [19,21]. Therefore, women in whom convulsions develop in association with hypertension and/or proteinuria or with headaches or blurred vision after 48 h of delivery should be considered to have eclampsia and initially treated as such [22].

Differential diagnosis

The presenting symptoms, clinical findings, and many of the laboratory findings overlap with a number of medical and surgical conditions [21,23-25]. The most common cause of convulsions developing in association with hypertension and/or proteinuria during pregnancy or immediately postpartum is eclampsia. Rarely, other etiologies producing convulsions in pregnancy or postpartum may mimic eclampsia. These diagnoses are particularly important in the presence of focal neurologic deficits, prolonged coma, or atypical eclampsia. In addition, in some patients gestational hypertension

or preeclampsia may develop in association with these disorders (connective tissue disease, thrombophilias, seizure disorder, hypertensive encephalopathy), further contributing to the diagnostic difficulty [23]. Therefore, an effort should be made to identify an accurate diagnosis, given that management strategies may differ among these conditions. The diagnosis and management of the conditions that mimic eclampsia are beyond the scope of this report [26].

Differential diagnosis of eclampsia

Cerebrovascular accidents

- a. Hemorrhage
- b. Ruptured aneurysm or malformation
- c. Arterial embolism or thrombosis
- d. Cerebral venous thrombosis
- e. Hypoxic ischemic encephalopathy
- f. Angiomas
- g. Hypertensive encephalopathy
- h. Seizure disorder
- i. Previously undiagnosed brain tumors
- j. Metastatic gestational trophoblastic disease
- k. Metabolic diseases
- l. Hypoglycemia, hyponatremia
- m. Reversible posterior leukoencephalopathy syndrome
- n. Thrombophilias
- o. Thrombotic thrombocytopenic purpura
- p. Postdural puncture syndrome
- q. Cerebral vasculitis [26].

Maternal-Perinatal Complications

Although eclampsia is associated with an increased risk of maternal death in developed countries (0-1.8%), the mortality rate is as high as 14% in developing countries. In developed countries, hemorrhagic stroke is the most common cause of death in patients with eclampsia and resulted in as many as 60% of all eclampsia-related deaths [8,18,19,27-30]. The high maternal mortality reported from developing countries is noted primarily among patients who had multiple seizures outside the hospital and those without prenatal care [18]. In addition, this high mortality rate could be attributed to the lack of resources and intensive care facilities needed to manage maternal complications from eclampsia [31]. Pregnancies complicated by eclampsia are also associated with increased rates of maternal morbidities, such as abruptio placentae (7-10%), disseminated intravascular coagulopathy (7-11%), pulmonary edema (3-5%), acute renal failure (5-9%), aspiration pneumonia (2-3%), and cardiopulmonary arrest (2-5%). The risks of diffuse intravascular coagulation (8%); hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (10-15%); and liver hematoma (1%) are similar in eclamptic and severely preeclampsia patients. It is important to note that maternal complications are significantly higher among women who develop antepartum eclampsia, particularly among those who develop eclampsia remote from term [8,14,28]. Perinatal mortality and morbidities remain high in eclamptic pregnancies. The reported perinatal death rate in recent series ranged from 5.6% to 11.8%.⁷⁷ this high perinatal death rate is related to prematurity, abruptio placentae, and severe fetal growth restriction. ^{65, 66} the rate of preterm delivery is approximately 50%, with approximately 25% of these occurring before 32 weeks of gestation [8,19,27,31].

Evaluation

Eclampsia always should be considered in a pregnant patient with a seizure episode. A pregnant patient who has been involved in an unexplained trauma (such as a single-vehicle auto accident) and has exhibited seizure activity should be evaluated for eclampsia. Eclampsia can occur during the antepartum, intrapartum, and postpartum periods. Ninety percent of eclampsia cases occur after 28 weeks' gestation. Preeclampsia can quickly develop into eclampsia. The natural progression of the disease is from symptomatic severe preeclampsia (differentiated from preeclampsia by specific vital signs, symptoms, and laboratory abnormalities) to seizures [1,13,32]. Features of eclampsia include the following:

- a. Seizure or postictal state (100%)
 - b. Headache (80%), usually frontal
 - c. Generalized edema (50%)
 - d. Vision disturbance (40%), such as blurred vision and photophobia
 - e. Right upper quadrant abdominal pain with nausea (20%)
 - f. Amnesia and other mental status changes
- I. The incidences of signs or symptoms before seizure include the following: 1, 13, 32
- a. Headache (83%)
 - b. Hyperactive reflexes (80%)
 - c. Marked proteinuria (52%)
 - d. Generalized edema (49%)
 - e. Visual disturbances (44%)
 - f. Right upper quadrant pain or epigastric pain (19%)
- II. The absence of signs or symptoms before seizure include the following [1,13,32]:
- a. Lack of edema (39%)
 - b. Absence of proteinuria (21%)
 - c. Normal reflexes (20%)
- III. The relation of seizure to delivery is as follows:
- a. Before delivery (>70%)
 - b. Before labor (antepartum) (25%)
 - c. During labor (intrapartum) (50%)
 - d. After delivery (postpartum) (25%)

Although patients with severe preeclampsia are at greater risk for seizures, 25% of patients have symptoms consistent with mild preeclampsia before the seizures. A study by Cooray et al found that the most common symptoms that

immediately precede eclamptic seizures are neurologic symptoms (ie, headache, with or without visual disturbance), regardless of degree of hypertension. This suggests that closely monitoring patients with these symptoms may provide an early warning for eclampsia [33].

Physical findings

Most patients with eclampsia present with hypertension and seizures, along with some combination of proteinuria and edema. Findings at physical examination may include the following [1,13,32]: Sustained systolic BP greater than 160 mm Hg or diastolic BP greater than 110 mm Hg.

- a. Tachycardia
- b. Tachypnea
- c. Rales
- d. Mental status changes
- e. Hyperreflexia
- f. Clonus
- g. Papilledema
- h. Oliguria or anuria
- i. Localizing neurologic deficits
- j. Right upper quadrant or epigastric abdominal tenderness
- k. Generalized edema
- l. Small fundal height for the estimated gestational age
- m. Apprehension

Cervical examination of the patient with eclampsia should not be overlooked, because the delivery mode may largely depend upon the patient's cervical status.

Management

The first priority in the management of eclampsia is to prevent maternal injury and to support respiratory and cardiovascular functions. During or immediately after the acute convulsive episode, supportive care should be given to prevent serious maternal injury and aspiration, assess and establish airway patency, and ensure maternal oxygenation. During this time, the bed's side rails should be elevated and padded, a padded tongue blade should be inserted between the teeth (avoid inducing gag reflex), and physical restraints may be needed. To minimize the risk of aspiration, the patient should lie in lateral decubitus position, and vomitus and oral secretion are suctioned as needed. During the convulsive episode, hypoventilation and respiratory acidosis often occur. Although the initial seizure lasts only a few minutes, it is important to maintain oxygenation by supplemental oxygen administration via a face mask with or without oxygen reservoir at 8-10 L/min

[22]. After the convulsion has ceased, the patient begins to breathe again and oxygenation is rarely a problem. However, maternal hypoxemia and acidosis may develop in women who have had repetitive convulsions and in those with aspiration pneumonia, pulmonary edema, or a combination of these factors. It is recommended using transcutaneous pulse oximetry to monitor oxygenation in all eclamptic patients [22].

Arterial blood gas analysis is required if the pulse oximetry results are abnormal (oxygen saturation at or below 92%). The next step in the management of eclampsia is to prevent recurrent convulsions. Magnesium sulfate is the drug of choice to treat and prevent subsequent convulsions in women with eclampsia [11,34,35]. It is recommended giving a loading dose of 6 g over 15-20 min, followed by a maintenance dose of 2 g/h as a continuous intravenous infusion. Approximately seminars inperinatology 37 (2013) 207-224 214, 10% of eclamptic women will have a second convulsion after receiving magnesium sulfate [36]. In these women, another bolus of 2g magnesium sulfate can be given intravenously over 3-5min. An occasional patient will have recurrent convulsions while receiving adequate doses of magnesium sulfate. In this patient, recurrent seizures can be treated with sodium amobarbital, given 250mg intravenously over 3-5min. Serum magnesium levels are not monitored during the infusion because there is no established serum magnesium level that is considered "therapeutic." Patients should be monitored for signs and symptoms of magnesium toxicity by serial evaluations of reflexes, respiratory rate, and urinary output. The signs and symptoms of magnesium toxicity in relationship to the magnesium level [37,38]. In case of magnesium toxicity, management is described. The next step in the management of eclampsia is to reduce the blood pressure, if hypertensive emergency is present. A hypertensive emergency is defined as sustained (430 min), severe hypertension (≥ 160 mmHg systolic or ≥ 110 mmHg diastolic) [37-39].

The objective of treating severe hypertension is to avoid the loss of cerebral autoregulation and to prevent congestive heart failure without compromising cerebral perfusion or jeopardizing uteroplacental blood flow that is already reduced in many women with eclampsia. If not treated expeditiously, it can result in complications such as cerebral hemorrhage and maternal death. Thus, morbidity and mortality risk reduction for women with eclampsia requires management and avoidance of severe systolic and diastolic hypertension. The aim of blood pressure management is to keep the BP in a safe range but at the same time to avoid significant hypotension. We recommend a target systolic blood pressure between 140 and 160 mmHg and diastolic blood pressure between 90 and 105 mmHg. The rationale for keeping maternal blood pressures at these levels is to avoid potential reduction in either uteroplacental blood flow or cerebral perfusion pressure. Acute first-line therapy includes IV labetalol and hydralazine as well as oral nifedipine [39].


Guideline recommendations for the dosing of IV labetalol are to begin with 20 mg intravenously followed at 10-min intervals by doses of 40 mg, then 80 mg, and then 80 mg for a total of 220-300 mg. A fall in blood pressure within 5-10 min is expected. If desired blood pressure levels are not achieved after 220 mg, switch to another drug. Intravenous hydralazine is also recommended, although a meta analysis has demonstrated a slight increase in adverse events compared with labetalol, but without sufficient data to recommend one drug over the other [39-41]. Hydralazine dosing begins with 5mg intravenously followed at 20-min intervals by a 5-10-mg bolus depending upon the initial response. A drop in blood pressure within 10-30 min is expected. If there is no success with a total of 25 mg intravenously, consider using another antihypertensive medication. A recent, double-blind, randomized controlled trial demonstrated similar effectiveness with oral nifedipine and intravenous labetalol regimens in the acute control of severe hypertension [42]. Oral rapid acting nifedipine dosing begins with 10-20 mg orally and continued every 30 min for a maximum dose of 50 mg in 1h. Other potent antihypertensive medications such as sodium nitroprusside or nitroglycerine are rarely needed in eclampsia. Diuretics are not used except in the presence of pulmonary edema. The introduction of guidelines in both the United States and the United Kingdom for the management of patients with eclampsia and increased awareness of the importance of blood pressure reduction has been associated with a decrease in the incidence of adverse maternal outcomes [43-46].

The next step in the management of a patient with eclampsia is to manage associated complications, such as disseminated intravascular coagulopathy (DIC) and pulmonary edema. If DIC is suspected, it is important to maintain blood volume and blood pressure with aggressive replacement with crystalloids and/or blood products as indicated. In general, the treatment of DIC is mainly supportive in nature. Specific details regarding the management of DIC are beyond the scope of this discussion. Initial management of pulmonary edema includes administration of oxygen and stimulating greater urine output by giving 20-40 mg of IV furosemide over 1-2 min. Further details regarding management of pulmonary edema is beyond the scope of this discussion. The next step in the management of an eclamptic patient is to begin induction/delivery within 24 h of the onset of eclampsia. Maternal hypoxemia and hypercarbia cause fetal heart rate and uterine activity changes during and immediately following a convulsion. Fetal heart rate changes can include bradycardia, transient late decelerations, decreased beat-to-beat variability, and compensatory tachycardia. Changes in uterine activity can include increased frequency and tone [47]. These changes usually resolve spontaneously within 3-10 min after the termination of convulsions and the correction of maternal hypoxemia. The patient should not be rushed for an emergency cesarean delivery based

on these findings, especially if the maternal condition is not stable. It is considered to be advantageous to the fetus to allow in utero recovery from hypoxia and hypercarbia due to maternal convulsions. However, if the bradycardia and/or recurrent late decelerations persist beyond 10-15 min despite all resuscitative efforts, then a diagnosis of abruptio placentae or no reassuring fetal status should be considered. The presence of eclampsia is not an indication for cesarean delivery. The decision to perform cesarean delivery should be based on fetal gestational age, fetal condition, presence of labor, and cervical Bishop Score. We recommend cesarean delivery for those with eclampsia before 30 weeks of gestation who are not in labor and whose Bishop score is below 5 [22].

Patients having labor or rupture of membranes are allowed to deliver vaginally in the absence of obstetric complications. When labor is indicated, it is initiated with either oxytocin infusions or prostaglandins in all patients with a gestational age of 30 weeks or more, irrespective of the Bishop score.

A similar approach is used for those before 30 weeks of gestation if the cervical Bishop score is at least 5. Maternal pain relief during labor and delivery can be provided by either systemic opioids or epidural anesthesia as recommended for women with severe preeclampsia. Epidural, spinal, or combined techniques of regional anesthesia can be used for cesarean delivery. Regional anesthesia is contraindicated in the presence of coagulopathy or severe thrombocytopenia (platelet count less than 50,000/mm³) [22]. In women with eclampsia, general anesthesia increases the risk of aspiration and failed intubation due to airway edema and is associated with marked increases in systemic and cerebral pressures during intubation and extubation. Women with airway or laryngeal edema may require awake intubation under fiber optic observation with the availability of immediate tracheostomy. Changes in systemic or cerebral pressures may be attenuated by pretreatment with labetalol or nitroglycerine injections.




The Use of Magnesium Sulphate for the Treatment of Eclampsia the Magpie Trial

Magnesium sulphate (MgSO_4) was first introduced to control convulsions in 1925, but it was the Collaborative Eclampsia Trial in 1995 that confirmed the efficacy of MgSO_4 in the treatment of severe preeclampsia and eclampsia. The trial (also called Magpie trial) was a randomized, placebo controlled study that enrolled over 10,000 women in 33 countries and across a wide variety of clinical settings. Four centers in Nigeria Ibadan, Sagamu, Port Harcourt and Sokoto participated in the study [48,49]. Women treated with MgSO_4 had a 52% and 67% lower recurrence of convulsions than those treated with diazepam and phenytoin, respectively. Use of MgSO_4 in patients with severe pre-eclampsia reduced the risk of progression to eclampsia by more than half and reduced maternal mortality. The effect of MgSO_4 on perinatal outcomes was also studied, demonstrating significantly improved outcomes for newborns compared to phenytoin. Recently, the 2-year outcome following the use of MgSO_4 in the Magpie trial was published. The reduction in the risk of eclampsia following prophylaxis with MgSO_4 was not associated with an excess of death or disability for the women after 2 years in the group that had MgSO_4 compared to placebo. The children whose mothers were treated with MgSO_4 were also studied at the age of 18 months. The use of the MgSO_4 was not associated with a difference in the risk of death or disability for the children at 18 months of age compared to those whose mothers were treated with placebo [29,34,49].

Mechanism of Action

The mechanism of action of $MgSO_4$ is not completely understood. It is thought to cause dilatation of cerebral blood vessels thus reducing cerebral ischemia. It is also thought that the magnesium blocks calcium receptors by inhibiting N-methyl-Daspartate receptors in the brain [50]. Magnesium also produces a peripheral (predominantly arteriolar) vasodilatation thus reducing the blood pressure [51]. It also acts competitively in blocking the entry of calcium into synaptic endings thus altering neuromuscular transmission. This transmission is affected by a preponderant presynaptic as well as a post-synaptic effect. The presynaptic release of acetylcholine is also reduced thus altering neuromuscular transmission [52]. The precise mechanism of action for the tocolytic effects of $MgSO_4$ is not clearly defined but may be related to the action of magnesium as a calcium blocker thus inhibiting muscle contractions [53].



Availability of MgSO₄

On the basis of the available evidence, The World Health Organization (WHO) has recommended MgSO₄ as the most effective, safe, and low-cost drug for the treatment of severe pre-eclampsia and eclampsia. There are indeed several reports of its successful introduction in several countries including Nigeria and its effectiveness and safety for mother and baby [54-57]. However, the drug has remained largely unavailable in several developing countries where it is incidentally needed the most. Leading advocates, researchers, non-governmental organizations, representatives of the WHO and national health ministry's from all over the world recently met and identified the main barriers to the use and availability of MgSO₄. These included the lack of guidelines on its use, non-inclusion in many national essential drug lists, the wrong perception that the drug is meant for use only at the highest level of facilities (such as those with intensive care facilities), lack of training of health workers on its use, little incentive for pharmaceutical companies to commercialize the drug, and ready availability of prepackaged forms of less effective drugs [58].


MgSO₄ regimens

There are principally two main regimens available for the administration of MgSO₄. In the Pritchard Regimen, the loading bolus dose of 4 g of MgSO₄ is given slowly intravenously over 5-10 min and this is followed by 10 g given intramuscularly (5 g in each buttock). Subsequently, 5 g is given intramuscularly into alternate buttocks every 4 h. In the Zuspan regimen, the loading dose consists of an initial intravenous dose of 4 g slowly over 5-10 min followed by a maintenance dose of 1-2 g every hour given by an infusion pump [59]. A gravity fed infusion set can be used in the absence of the pump especially in the developing countries. It should be noted that for the 50% MgSO₄, 1 ml of the solution contains 0.5 g of MgSO₄, while for the 20% solution, 1 ml contains 0.2 g of MgSO₄. Monitoring is important to ensure that the right doses are administered and this is not an easy task. Whatever regimen chosen, the drug should be administered till 24 h after delivery or after the last fit (whichever comes last). The choice of which regimen to use depends on a number of factors such as availability of staff to monitor the drug as well as the expertise of the staff. In resource-constrained settings, the Pritchard regimen may be easier to administer since it is given intramuscularly (could thus be administered by lower cadre of health workers). It, however, has the disadvantage of being very painful, a situation which is not desired for a patient on whom efforts are being made to lower the blood pressure. To counteract this, the intramuscular dose could be administered with about 2 ml of 1% xylocaine in the same syringe. Some workers have reported modifications in the above-mentioned regimens. MgSO₄ has been used with the dose reduced to a loading dose of 4.5 g intravenously and maintained on intramuscular 1.5 g every 4 h until 12 h after delivery or the last fit [60].

In another study, the loading dose was 10g intramuscularly followed by a maintenance dose of 2.5 g intramuscularly every 4 h for 24 h. The drug has been used as in Pritchard regime, but the duration of its administration reduced to 12 h after the initial loading dose. The fetomaternal outcome was similar to the two more famous regimens (Pritchard and Zuspan) [61,62].


Clinical Detection of Toxicity

The main fear of toxicity was also laid to rest with the Magpie trial. Toxicity of the drug was monitored using clinical parameters. The parameters that need to be monitored are the knee jerk (should be present), respiratory rate (should be more than 16/minute), and urine output (should be more than 25 ml/min). These clinical parameters have been compared with serum levels of MgSO_4 . The first warning sign of toxicity is loss of the knee jerk which occurs at serum magnesium level of 3.5-5 mmol/l. Respiratory paralysis occurs at 5-6.5 mmol/, cardiac conduction is altered at more than 7.5 mmol/ while cardiac arrest occurs when serum magnesium exceeds 12.5 mmol/l. However, with the above-mentioned protocols, the expected serum range of magnesium is 2-3.5 mmol/l. Using the Pritchard regimen, a mean serum magnesium level of 2.1 mmol/l was found. Should toxicity be detected, however, the antidote is 1 g of 10% calcium gluconate given intravenously slowly over 10 minutes [48,63,64].



Training on MgSO₄

The need has now emerged for refresher trainings for health workers in the use of MgSO₄. Clinical protocols are particularly useful in guiding such workers. The Federal Ministry of Health has developed a national clinical service protocol for obstetric care. The protocol outlines the management of eclampsia and how MgSO₄ can be used and monitored. There is need to distribute this protocol and train health workers all over the country on its use. It is also recommended that the protocol should be utilized nationally as a guideline thus ensuring universal dosage regimen that will also help in uniform studies and research. Some workers have also reported the utilization of the protocol to suite the working environment in respect of the available facilities, staff, investigations, and even the regimen of MgSO₄ used. In Kano state, for example, the protocol was institutionalized under the guidance of the state safe motherhood committee to incorporate the role played by non-physicians in the care of patients with eclampsia including referral where necessary [65].



Objective

- a. To study MgSO_4 versus Diazepam/ in reducing maternal neonatal mortality in Eclampsia.
- b. To screen, evaluate/manage high risk cases of eclampsia according to a set proforma/Protocol by using MgSO_4 Vs Diazepam.
- c. To study materno-foetal outcome by using MgSO_4 Vs Diazepam.

Material & Methods

Study period

Three years from January 2005 to December 2009 2005 to 2009 in Unit -II 2 LWH, KEMU.

Study design

500 patients of Eclampsia were studied included booked / un-booked patients attending Lady Willingdon Hospital were admitted evaluated and put on MgSO₄ Vs Diazepam and divided in two groups. The results were compared which showed a MgSO₄ superior as compared to Diazepam in improving overall mortality morbidity in Eclampsia. Our study included 500 cases eclampsia with of convulsive disorders with diagnosis of pregnancy or at any time during first 6 weeks post Partum admitted during year Jan 2005 to Dec 2009 at Lady Willingdon Hospital only, Those patients were excluded which turned out to be cerebral thrombosis "Epileptic on medical record. Lady Willingdon Hospital is a tertiary care referral hospital affiliated with KEMU. Journal of obstetrics & Gynecology Deployment of MRI & TCD for Eclampsia Pt should enable a precise diagnosis and exclude many other sinister conditions and allow more precise monitoring. Maternal mortality rate MMR <1% to 20% 130 to 300/1000. Other diagnostic Technique is improving rapidly clinical skills to interpret results, Doctor from different specialties working together.

I. Ruling out other serious conditions

- i. Epilepsy
- ii. Infections
- iii. Meningitis
 - a. Bacterial / viral
 - b. Tuberculous
 - c. Fungal abscesses
- iv. Cerebral Tumours Meningitis
- v. Rupture cerebral aneurysms
- vi. CVAS
 - a. Thrombosis
 - b. Hemorrhages
 - c. Embolism
 - d. Tumours
- vii. Sub arachnoid hemorrhage
- viii. Metabolic, Disease Cerebral Malaria
- ix. Liver / Kidney Failures.
- x. Drugs

Until the causes excluded all pregnant women with

convulsions should be considered to have Eclampsia, and diagnosis is crucial, as occurrence of eclampsia, epilepsy is different.

Procedure of Data Collection

All the patients of pregnancy between 28 weeks to 39 weeks with Eclampsia were admitted in ICU and managed according to set protocol and were given MgSO₄ and Diazepam divided in two groups and their role compared. Blood Pressure was controlled with Hydralazine, Labetalol, Isoket infusion. Results were given in table form. Of the total patients 50 were excluded from the study, 10 of them could not be traced in the follow up and their outcome is not known. 20 had been induced, pre-term delivery due to medical conditions i.e. uncontrolled hypertension & albuminuria due to eclampsia.

All patents were examined and investigated thoroughly, managed and regular follow up ensured while comparison is made between the role of MgSO₄ & Diazepam in patients. The study conducted in accordance with standard criteria / protocols set up and Data analyzed by recording on a especially designed proforma for evaluation and later analysis and comparison made between when the acute emergency is over, the patients are stabilized managed accordingly till convalescence and followed regularly.

The maternal fetal outcome / prognosis depend upon the severity of signs and Gestational age. Mostly the uncomplicated pregnancy were carried to the terms also if maternal and fetal condition allows i.e. 37 completed weeks and the 34 completed week was taken a cutoff point to prematurity and role & comparison of use of MgSO₄ Vs Diazepam in eclampsia, analyzed. Regular antenatal care in high risk pregnancy admission of Eclampsia use of MgSO₄ Vs Diazepam control of blood pressure by Hydralazine and Labetalol and urgent delivery markedly reduces MMR, NMR. All women fulfilling the study criteria were counseled especially the OPD patients and meet the average ages between the age (28 - 39) of gestation. Complete set of history as shown in the Performa, including precious, obstetric, Gynecological/ medical/especially previous history of hypertension/PIH, Fits unconsciousness. PET/ Eclampsia/ surgical/drug and psychological history was obtained at first antenatal or first emergency admission (in case of coma from the relatives available) and entered on to a proforma. Gestational age was determined from menstrual history and confirmed by:

- a. Dating / Growth, follow up scan
- b. BPD (Biparietal) (FL Femur length) in the last Trimester Scan.

As part of routine/emergency care, full thorough and detailed General physical examination was conducted followed by systemic examinations of CVS, GIT, respiratory and special emphasis was laid on CNS examination and Fundo-Scopic points to be particularly important were following points.

- a. Neck rigidity
- b. Level of consciousness.
- c. Reflexes superficial, Deep tenden reflexes/Ankle Clonus Plantars Reflex
- d. Input/ Output
- e. Respiratory rate
- f. Obstetrical complications like bleeding P/V. Pains / Leaking

- HELLP Syndrome, DIC,
- And Failures, cardiac/respiratory renal/hepatic, acute pulmonary edema. Thrombo - embolic - phenomena's.

These symptoms and signs are not only prognostic markers but also helps in monitoring of Management especially Mag sulphate and Diazepam which is the drug of choice for convulsions. The patient being managed according to a management protocol which includes (19).

- a. Expectant (After ruling out fulminant Preeclampsia) Management
- b. General Management Fulminant (Eclampsia management & role and usage of Magnesium Sulphate Vs Diazepam ICU.
 - Medical / Management
 - Obstetrical

Follow up according to management in high dependency unit with multi specialty involvement according to severity of symptoms and gestational age.

- a. Expectant Management is continuous till maternal / foetal conditions allows and expected maternity achieved.
- b. Medical includes also of Management of Fulminant cases of eclampsia.

Preferably in ICU HDU and equipped with Resuscitation/ monitoring equipment e.g. monitors, Resuscitators/ ventilators defibrillators/suckers etc. Strict monitoring of fluid balance is essential, as fluid over load leads to pulmonary edema, careful Monitoring is preferred, CVP as Cardio - Vascular system is very labile gives way in seconds, and can be prevented. Data was collected from 500 consecutive eclamptic patients admitted to Lady Willingdon Hospital during the year Jan 2005 to a 2009. L.W.H. is a 235 bedded tertian care hospital attached to KEMU Lahore. It receives complicated and many serious cases coming from distant places, on admission a detailed history was taken from patient or medics attendants/relatives accompanying with any available record, then a thorough clinical and detailed general and systemic examinations and a bed side test of Proteinuria (urine R/E) dipstic method while measuring BP, until Korotkoff "V" sound heard, Neurologist/Physicians were involved in patients care where deemed necessary. During the period of study MgSO₄ or/Diazepam was used as anticonvulsant and Hydralazine infusion, Nefidipine was used as antihypertensive, Data was collected on a specifically designed self administered Performa. The cause of death was determined by a clinical history/ exanimations/ investigations and previous management if any etc. Post mortem examination was not under taken in any case; statistical analysis was carried out using chi-squared test of significance.

Data Analysis

Identifying the risk factors during meticulous antenatal screening and looking for increase in hypertension, proteinuria and evaluating the warning signs of pre-eclampsia and eclampsia. The drugs are the $MgSO_4$ and Diazepam for control of fits, control of blood pressure Hydralazine, Labetalol, Isoket infusion and study of $MgSO_4$ and Diazepam already discussed in details.

Results (Tables 1-3 & Figure 1)

Table 1: Status of Pregnant Women.

	Group-A	Group-B	Total
Booked	150	180	330
Un-booked	100	70	170
Total	250	250	500

Group-A= MgSO₄

Group-B= Diazepam

In Group-A there were 150 women who had booked for their delivery while the remaining 100 women were un-booked for their delivery. In Group-B there were 180 women who had booked for their delivery while 70 women were not booked for their delivery.

Table 2: Maternal Mortality Status in Treatment Groups.

		Group-A	Group-B	Total
Mortality	Yes	20(8%)	40(16%)	60
	No	230(92%)	210(84%)	440
Total		250	250	500

Group-A= MgSO₄

Group-B= Diazepam

Chi-Square Test=7.576

p-value= 0.005

In Group-A there were 20 mothers and in Group-B 40 mothers died. It was observed that maternal mortality was significantly higher in Group-B women as compared to that of Group-A. i.e. (p-value=0.005).

Table 3: Perinatal mortality in treatment groups.

		Group-A	Group-B	Total
Mortality	Yes	25	45	80
	No	195	165	360
Total		230	210	440

Group-A= MgSO₄

Group-B= Diazepam

Chi-Square Test=9.148

p-value= 0.002

In Group-A perinatal mortality was seen in 25 neonates while in Group-B perinatal mortality was seen in 45 neonates. According to p-value it was observed that perinatal mortality was significantly lower in Group-A as compared to Group-B. i.e. (p-value=0.002).




Figure 1: Mortality status in patients.
Maternal mortality was seen in 12% women

Discussion

Pre-eclampsia is a condition unique to pregnancy that is characterized by new onset of hypertension and proteinuria [66]. Pre-eclampsia is a relatively common complication of pregnancy, and can occur at any time during the second half of pregnancy or in the first few weeks after delivery. For many women who have pre-eclampsia the maternal outcome is good, but severe disease can lead to death or serious problems for the woman. Severe pre-eclampsia is associated with multiple organ system involvement including renal failure, cerebral hemorrhage and edema, hepatic failure and rupture, and thrombocytopenia in addition to pre-eclampsia [67]. Pre-eclampsia and eclampsia are not distinct disorders but the manifestations of the same condition. In pre-eclampsia, hypertension and proteinuria are present, and when convulsions occur after other causes of convulsion are excluded in addition to these signs, the condition is referred to as eclampsia [66]. Eclampsia is a serious complication increasing the risk of maternal morbidity and mortality [68]. Current strategies for prevention of pre-eclampsia can be broadly classified as antenatal surveillance, modification of lifestyle, nutritional supplementation, and pharmacological therapy. The only definitive treatment for pre-eclampsia or eclampsia is to end the pregnancy. The aim of interventions for women with eclampsia is to prevent further seizures, to minimize and treat any complications and, if not delivered, to optimize the timing of birth for the baby. Currently, standard care for women with severe pre-eclampsia/eclampsia is to use an anticonvulsant drug to control the immediate fit, and to continue maintenance treatment to prevent further seizures [68].

The principal goals of treatment in eclampsia are stopping the convulsions and preventing further fits which are associated with reduction in adverse outcome. This has been reported to depend on the type of anticonvulsant used. It has also been revealed, in a typical systematic quantitative review and analysis, that magnesium sulphate was more effective than other interventions in preventing recurrent seizures in eclampsia and in preventing the first seizure in pre-eclampsia. Another meta-analysis by Duley et al. [34] has reported a substantial reduction in the risk recurrence of further fits (RR=0.44, 95%CI 0.34 to 0.57) in eclamptic pregnant women [34,69]. In this study it was observed that maternal and perinatal mortality was high in Group-B (diazepam) however In Group-A (MgSO₄) maternal and perinatal mortality was low. This difference in mortality in both treatment groups was statistically significant. According to Khan, magnesium sulphate was the better anticonvulsant than diazepam infusion in terms of total morbidity and maternal deaths (Null versus 5%) [70].

A Randomized Double Blind Trial of Magnesium Sulphate and Diazepam in Lagos, Nigeria also showed that the use of

magnesium sulphate was found to be significantly associated with less serious morbidity in comparison to diazepam use [71]. A similar significant reduction in maternal deaths was reported in Tanzania [72]. Gizat M Kassie in his study evaluated maternal outcomes of magnesium sulphate and diazepam use in the management of severe pre-eclampsia and eclampsia in Jimma University Specialized Hospital. In his results he reported that Three pregnant women from the magnesium sulphate treated group and eleven pregnant women from diazepam treated group had at least one convulsion after taking the drug. Greater proportion of patients in the magnesium sulphate treated group had less than four days postpartum stay as compared to the diazepam treated patients (82.3% versus 66.2%). Seizure occurrence, duration of postpartum hospital stays and birth outcome had a statistically significant association with the type of anticonvulsant used [73].


Chaudhary P [57] in his study determined the incidence and impact of changes in the intervention strategy for the management of eclampsia in a maternity hospital on maternal and perinatal outcome. In his results he reported that marked improvement was noticed in terms of recurrence of fit (19.13% vs 73.91%) with change in the intervention strategy. Perinatal deaths were fewer in study period B (20% vs 33%). Overall, it seems that care of eclamptic patients and use of magnesium sulphate as anticonvulsant has resulted in positive impact on maternal outcome. Eclampsia is still commonly perceived as the end of a linear spectrum that stretches from normal pregnancy, through mild hypertension, pre-eclampsia and finally eclampsia. However, eclampsia may precede pre-eclampsia and an alternative view is that seizures are one of the range of signs and symptoms caused by the widespread endothelial cell damage secondary to an ischaemic placenta. Pre-eclampsia is a multisystem disease of poorly understood etiology and the extent of involvement of various organs are unpredictable. Another important fact is that treatment of this disease is entirely empirical and symptomatic and controversy still exists in the choice of the most appropriate treatment especially for prevention and control of fits. It is understood that treatment of eclampsia is symptomatic as underlying cause is unknown. Most clinicians agree that diazepam should be used to abort initial fit as it is effective, inexpensive, and easily available and can be used by nursing staff. However, the risks include respiratory depression, respiratory arrest and aspiration pneumonia. The general aim of treatment in eclampsia is prevention of further fits as it is the recurrent fits that leads to significant cerebral anoxia and its associated adverse outcome. The greater efficacy of magnesium sulphate compared to diazepam or phenytoin for prevention of recurrence of fits is now accepted worldwide in many studies.

Conclusion

The comparative study and of role of $MgSO_4$ Vs Diazepam in reducing mortality, morbidity in matenetis, neonetis showed the efficacy and superiorness of magnesium sulphate as compared to Diazepam without any doubt.

Guidelines for the immediate management of ECLAMPSIA and IMMINENT ECLAMPSIA

1/99




Examine A patient of Pih / Pet Pregnancy Induced Hypertension Pre-Eclamptic Toxemia/ Eclampsia Re-Renal E-Endocrine C-Coaractation A-P Poly Cystic(R-E-C-A-P)

- Fundi
Fundoscopy
1. Silver Wiring
 2. A.V Nipping
 3. Soft Exudates
 4. Pupilloedema

- B.P 130/90
Anemia Lying
Tongue Standing
Both Arms
Goitre Thyroid
Carotid
- Radial Pulse
 - Radial to Radial
 - Radio Femoral
 - Fistula
- Fundal Height
Singleton
Twins
Lie USG
Doppler Device
Or Pinnard Baby's
Heart
Any Uterine tenderness
Or Masses
Fibroids / Cysts
Papation over uterus
Presentation Appearance
General Appearance
Azote mic / uremic
Cushingoid
Upper body hypertrophy
Obese
Also Check Optic Disc (Fundi)
Listen The Lung Bases
Check Reflexes Upper and Lower
Lambs
Height Check clonus
WT: Paplate and over liver
Stand on right side epigastive

EXAMINATION OF PATIENT OF PET / ECLAMPSIA



- Conscious Level Fits
Xanthelasma
USG
Dating / Growth
IUFD / IU GR
Grips

Pericardium

- Breast A1A2 / Murmurs
S4
Lungs (Crepts AT Bases)
Plumony Oedema
Inspection
Renal bruit / Polycystic
Renal Artery Steonsis
Liver Spleen
Femoral Bruit of Aorta
Distention of Abdomen
Fetal Movements
Scars Low suprapubic
Marks Grid Iron / Midline
Pigmentation
Linea Nigra
Dip Stick
Urine Examination

Calf tenderness

Oedema

Examine a Patient of Hypertension and gestational Diabetes: Pih + Gdm

- Eyes: Visual Acuity
- Ocular Movement
- Fundo-Scopy-Retinopathy
 - Cataract
 - Retinopathy
 - New vessels
 - Hard Exudates
 - Macular Oedema

- USG Scans
- Dating / Growth
- Anomaly
- Cardiac Anomaly
- Growths - LFD
- Dental Hygiene
- Thrush

Fungal Infections

Waxy Skins

Injections

- Infections
- NIDDM/BP-PIH
- IDM
- BSF
- BSR

Fistula

Hands

Sweaty Palms

Pulse

- Appearance
- Cushingoid
- Uremic
- Balding
- Obese

HBA1C

[< 6%]


Poor Control > 8%

GCT 40 mg

OGTT 95-180

155-140

EXAMINATION OF PATIENT OF PET / ECLAMPSIA



COMPLICATIONS

- Signs of Neuropathy
- Nephropathy
- Vasculopathy
- Dermopathy
- Myopathy

Carotid
Thyroid Bruit

(Cardio-Megaly)

Lungs Throctotomy
(CAB)

Twins
Large For Dates

Still Birth
Poly Hydromnios
Abdomen
Hepatho-Megaly
Palpable Kidneys

Femoral Bruit

Enlarged Bladder

Legs: Amputation
Wasting
Skin
Colour
Ulcer
Warmth
Oedema

Guide Lines/Key Points Symptomatology/Management Protocol Pre Eclampsia Eclampsia

Review MgSO₄ Vs diazepam key points

Eclampsia is defined as generalized seizures accompanied with fulminate Pre-eclampsia. Pre-eclampsia eclampsia developing after 20 weeks and at the end of 1st week of postpartum treatment is I/V Mg Sulphate I/V Hydralazine / Labetalol and rapid delivery.

Key Points Score

Criteria to score Preeclampsia

New onset protinuric hypertension and at least one of the following:

Symptoms of central nervous system dysfunction:

Blurred vision, scotomata, altered mental status, severe headache

Symptoms of liver capsule distention:

Right upper quadrant or epigastric pain

Hepatocellular injury:

Serum transaminase concentration at least twice normal

Severe blood pressure elevation:

Systolic blood pressure 160 mm Hg or diastolic 110 mg Hg

On two occasions at least six hours apart

Thrombocytopenia:

Less than 100,000 platelets per cubic millimeter

Proteinuria:

Over 5 grams in 24 hours or 3+ or more on two random samples four hours apart

Oliguria <500 mL in 24 hours

Intrauterine fetal growth restriction

Pulmonary edema or cyanosis

Cerebrovascular accidents (CVAS)

Coagulopathy / DIC (Disseminated Intravascular Coagulation)

Protocol Eclampsia

- Immediate Care maintain airway maintain left lateral position oxygen administration
- Abort convulsions diazepam 10 mg. 1.v. or clonazepam 1 mg i.v.
- Seizure prophylaxis / therapeutics. magnesium sulphate
- Maintain diastolic blood pressure of 95-105 mmHg
- Coagulation screen/renal function / platelet count.
- Haemodynamic stabilization followed by delivery within 6-8 h.
- Postpartum 24-48 h of intensive care
- N.B. Ventilatory support for at.
- Least 24 hours if poor arterial blood gases.
- Unconsciousness/Glasgow Come scale <8.
- Extreme restlessness.
- Laryngeal oedema.

Anti Hypertensive in Eclampsia

Class	Drug	Starting dose	Maximum does (24h)
Centrally Acting	Methyldopa	250 mg qid	4 gm
Alpha receptor blocker	Prozasoin Hcl	1mg bd	20mg
Calcium Channel Blockers	Nifedipine (Nifedipine)	10mg tds	120mg
$\alpha\beta$ Blockers	Labetolol	200mg tds	2400mg

Anti Convulsants

Drug		
MgSO ₄	5gm I/V 5g,	1-2 g, /hr
Diazepam	10mg D/V Show	30 mg- Max
Phenytoin 300 mg I/M	-	-
Clonazepam	1 mg	Rivotril infusion

Continued Key Points

- Key Points for Clinical Practice
- There may be a strong family history.
- Hypertension may not be the primary presenting symptom.
- The placenta is the initial trigger to disease development.
- The presentation of pre-eclampsia is very varied and any body system can be affected.
- Maternal response is the main controller of disease severity.
- Upper abdominal pain is a concerning feature suggestive of HELLP syndrome.
- Eclampsia is not an inevitable progression from pre-eclampsia.
- Pulmonary oedema can occur with a normal CVP due to capillary leak.

Recommendations for Management

Key Point For Clinical Practice

We make the following recommendations for the management of patients with eclampsia and severe pre-eclampsia:

- All severe Fulminant pre-eclampsia and eclampsia should be managed in special regional centers with the appropriate expertise.
- Continuous monitoring of blood pressure pulse rate, ECG and central venous pressure is required as the cardiovascular system is extremely labile in this condition and can deteriorate in seconds.
- Magnesium Sulphate is the drug of choice, in fulminant pre eclampsia / eclampsia.
- Magnesium Sulphate both prophylactically therapeutically, evidenced based, proved beyond any doubt.
- The airway should be maintained and protected. Any patient with a Glasgow Coma Scale of less than 9 should be intubated. Nursing staff at district hospitals and community clinics should be taught how to position an unconscious patient, insert oral airway and administer oxygen.
- An arterial partial pressure of oxygen of at least 100 mmHg should be maintained. Mechanical ventilation may be necessary.
- Blood pressure should be carefully and slowly lowered the diastolic pressure should be lowered by not more than 30 mmHg in order to maintain cerebral perfusion.
- Seizures should be prevented or terminated as soon as possible MgSO₄ is the anticonvulsant of choice for this purpose. Efficient transport facilities must be available and personnel at district hospitals and community clinics should be capable of administering anticonvulsants.
- The fetus should be delivered within 6-12 hrs of admission: Caesarean section is often indicated. General anesthesia, administered by skilled anesthetist, is recommended. Where these facilities are not available, epidural anesthesia would be adequate, provided a hypertensive episode is prevented with sufficient intravenous pre-loading and coagulopathy is excluded by estimation of crude clotting time, fibrinogen levels and platelet counts.
- An eclampsia team should be organized, since the problems developed by these patients are multifactorial. Personnel (an obstetrician, obstetric anesthetist and critical care nurse) experienced in the specific obstetric management of these patients need to work together, in order to improve patient outcome. While prevention of pre-eclampsia/eclampsia must await an understanding of its etiology, improvement in antenatal care, together with active management of the disease when it develops, will improve both fetal and maternal prognosis.

Pre Eclampsia/Eclampsia-Dic

- Aetiology Thromboplastins, thrombin, fibrin
- Pathology Intra vascular fibrin
- Pregnancy association Abruptio placentae
- Fibrinogen levels Low
- Platelet count Mild to moderately decreased
- Red cells Slight to moderate fragmentation
- Micro-angiopathy
- Aetiology Endothelial cell damage, platelet activation, deficient production of vasodilator autocooids
- Pathology Intravascular platelet aggregation and deposition
- Pregnancy association Pre-eclampsia/HELLP syndrome
- Fibrinogen levels Normal or high
- Platelet count Moderate to markedly decreased
- Red cells Moderate to marked fragmentation

For


- More common in primigravida
- More common in twin pregnancies
- Incidence increased by change of partner
- A higher incidence of HLA homozygosity

Against

- No increase in ABO. HLA or Y-linked compatibility
- The incidence is similar in monozygotic and dizygotic twin pregnancies
- Similar placental findings are found in intra-uterine growth retardation.

Key Points – MgSO₄ Vs Diazepam

- Eclampsia is an obstetrical emergency that occurs in 4 to 5 per 10,000 live births in developed countries, with higher rates in under developing countries.
- Approximately one-third of cases are not preventable.
- Both the fetus and the mother are at immediate risk of death or life-long neurologic disability.
- The goals of management are to stabilize the mother, prevent recurrent convulsions, treat severe hypertension, and initiate delivery of the fetus.
- Delivery is the only curative treatment, but immediate cesarean birth is not usually necessary.
- Maternal prognosis is good with prompt treatment and in the absence of cerebrovascular hemorrhage. The fetal prognosis is primarily dependent upon the gestational age at delivery.
- Two percent of women will experience an eclamptic seizure in a future pregnancy, 9 to 25 percent will develop severe preeclampsia, and up to 65 percent will develop preeclampsia.
- Magnesium sulfate is the drug of choice for prevention of both primary and recurrent eclamptic seizures as compared to diazepam Phenytoin.



References

1. <http://emedicine.medscape.com/article/253960-overview>
2. Jido T, Yakasai I (2013) Preeclampsia: a review of the evidence. *Ann Afr Med* 12(2): 75-85.
3. ACOG Committee on Practice Bulletins-Obstetrics (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. *Obstet Gynecol* 99(1): 159-167.
4. Main EK. Maternal (2010) Mortality: new strategies for measurement and prevention. *Curr Opin Obstet Gynecol* 22(6): 511-516.
5. O'Connor HD, Hehir MP, Kent EM, Foley ME, Fitzpatrick C (2013) Eclampsia: trends in incidence and outcomes over 30 years. *Am J Perinatol* 30(8): 661-664.
6. Richards A, Graham D, Bullock R (1988) Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. *J Neurol Neurosurg Psychiatry* 51(3): 416-421.
7. Liu S, Joseph K, Liston RM, Bartholomew S, Walker M, et al. (2011) Incidence, risk factors, and associated complications of eclampsia. *Obstet Gynecol* 118(5): 987-994.
8. Douglas KA, Redman CW (1994) Eclampsia in the United Kingdom. *BMJ* 309(6966): 1395-1400.
9. Sibai BM (2004) Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. *Am J Obstet Gynecol* 190(6): 1520-1526.
10. Tan KH, Kwek K, Yeo GS (2006) Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital Singapore. *Singapore Med J* 47(1): 48-53.
11. Altman D, Carroli G, Duley L, Farrell B, Moodley J, et al. (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Maggie Trial: a randomised placebo-controlled trial. *Lancet* 359(9321): 1877-1890.
12. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD (2009) Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. *BMC Pregnancy Childbirth* 9(1): 11.
13. Gabbe SG, Niebyl JR, Galan HL, Jauniaux ER, Landon MB (2012) *Obstetrics: normal and problem pregnancies*. (6th edn), Elsevier Health Sciences, USA.
14. Mattar F, Sibai BM (2000) Eclampsia VIII. Risk factors for maternal morbidity. *Am J Obstet Gynecol* 182(2): 307-312.
15. Banerjee S, Randeve H, Chambers AE (2009) Mouse models for preeclampsia: disruption of redox-regulated signaling. *Reprod Biol Endocrinol* 7: 4.
16. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S (2009) Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. *PLoS One* 4(2): e4453.
17. Cadden KA, Walsh SW (2008) Neutrophils, but not lymphocytes or monocytes, infiltrate maternal systemic vasculature in women with preeclampsia. *Hypertension in Pregnancy* 27(4): 396-405.
18. Katz VL, Farmer R, Kuller JA (2000) Preeclampsia into eclampsia: toward a new paradigm. *Am J Obstet Gynecol* 182(6): 1389-1396.
19. Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM (2002) Late postpartum eclampsia: a preventable disease. *Am J Obstet Gynecol* 186(6): 1174-1117.
20. Thornton C, Dahlen H, Korda A, Hennessy A (2013) The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008. *Am J Obstet Gynecol* 208(6): 476.
21. Lubarsky SL, Barton JR, Friedman SA, Nasreddine S, Ramadan MK et al. (1994) Late postpartum eclampsia revisited. *Obstet Gynecol* 83(4): 502-505.
22. Hart LA, Sibai BM (2013) Seizures in pregnancy: epilepsy, eclampsia, and stroke. *Seminars in perinatol* 37(4): 207-224.
23. Wittlin AG, Friedman SA, Egerman RS, Frangieh AY, Sibai BM (1997) Cerebrovascular disorders complicating pregnancy-beyond eclampsia. *Am J Obstet Gynecol* 176(6): 1139-1148.
24. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, et al. (1996) A reversible posterior leukoencephalopathy syndrome. *N Engl J Med* 334(8): 494-500.
25. Stott V, Hurrell M, Anderson T (2005) Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. *Intern Med J* 35(2): 83-90.
26. Sibai BM (2005) Diagnosis, prevention, and management of eclampsia. *Obstet Gynecol* 105(2): 402-410.
27. Leitch C, Cameron A, Walker J (1997) Pattern of eclampsia the changing over a 60-year period. *BJOG: An International Journal of Obstetrics & Gynaecology* 104(8): 917-922.
28. Lopez-Llera M (1992) Main clinical types and subtypes of eclampsia. *Am J Obstet Gynecol* 166(1): 4-9.
29. (1995) Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. *Lancet* 345(963): 1455-1463.
30. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W et al. (2005) Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. *Obstet Gynecol* 105(2): 246-254.
31. Sibai BM (1990) Eclampsia VI Maternal-perinatal outcome in 254 consecutive cases. *Am J Obstet Gynecol* 163(3): 1049-1054.
32. Stead LG (2011) Seizures in pregnancy/eclampsia. *Emergency medicine clinics* 29(1): 109-116.
33. Cooray SD, Edmonds SM, Tong S, Samarasekera SP, Whitehead CL (2011) Characterization of symptoms immediately preceding eclampsia. *Obstet Gynecol* 118(5): 995-999.
34. Duley L, Gulmezoglu A, Henderson-Smart D (2010) Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 10: 11
35. Lucas MJ, Leveno KJ, Cunningham FG (1995) A comparison of magnesium sulfates with phenytoin for the prevention of eclampsia. *N Engl J Med* 333(4): 201-215.

36. Wittlin A, Saibai B (1998) Magnesium sulfate therapy in preeclampsia and eclampsia. *Obstet Gynecol* 92(5): 883-889.
37. Ono Y (2008) Management of eclampsia.
38. Yaqui S, Zafar B Mahmood KT Amin F (2011) Management of Eclampsia. *Journal of Pharmaceuticals Science and Technology* 3(1): 528-535.
39. American College of Obstetricians and Gynecologists (2012) Obstetricians ACOG Gynecologists ACOG Practice Bulletin No125 Chronic hypertension in pregnancy. *Obstet Gynecol* 119(2 Pt 1): 396-407.
40. Committee on Obstetric Practice (2011) Committee Opinion no. 514: emergent therapy for acute-onset severe hypertension with preeclampsia or eclampsia. *Obstet Gynecol* 118(6): 1465-1468.
41. Magee LA, Cham C, Waterman EJ, Ohlsson A Von, Dadelszen P (2003) Hydralazine for treatment of severe hypertension in pregnancy meta-analysis. *BMJ* 327(7421): 955-960.
42. Raheem IA, Saaid R, Omar SZ, Tan PC (2012) Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy a randomized trial. *BJOG* 119(1): 78-85.
43. Menzies J, Magee LA, Li J, MacNab YC, Yin R, et al. (2007) Stuart H Instituting surveillance guidelines and adverse outcomes in preeclampsia. *Obstet Gynecol* 110(1): 121-127.
44. von Dadelszen P, Sawchuck D, McMaster R, Douglas MJ, Lee SK, et al. (2010) The active implementation of pregnancy hypertension guidelines in British Columbia. *Obstet Gynecol* 116(3): 659-666.
45. Wilkinson H, Trustees and Medical Advisers (2011) Saving mothers' lives Reviewing maternal deaths to make motherhood safer 2006-2008. *BJOG* 118(11): 1402-1403.
46. McClure J, Cooper G, Clutton-Brock T (2011) Saving Mothers' Lives reviewing maternal deaths to make motherhood safer 2006-2008 a review. *Br. J. Anaesth* 107(2): 127-132.
47. Paul RH, Koh KS, Bernstein SG (1978) Changes in fetal heart rate-uterine contraction patterns associated with eclampsia. *Am J Obstet Gynecol* 130(2): 165-169.
48. Ekele B (2006) Magnesium sulphate the gold standard for the treatment of eclampsia and severe pre-eclampsia. *Trop J Obstet Gynaecol* 23(1): 1-2.
49. Magpie Trial Follow-Up Study Collaborative Group (2007) The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. *BJOG* 114(3): 300-309.
50. Sadeh M (1989) Action of magnesium sulfate in the treatment of preeclampsia-eclampsia. *Stroke* 20(9): 1273-1275.
51. Vigorito C, Giordano A, Ferraro P, Acanfora D, De Caprio L et al. (1991) Hemodynamic effects of magnesium sulfate on the normal human heart. *Am J Cardiol* 67(16): 1435-1437.
52. Krendel DA (1990) Hypermagnesemia and neuromuscular transmission. *Semin Neurol* 10(1): 42-45.
53. Dube L, Granry JC (2003) The therapeutic use of magnesium in anesthesiology intensive care and emergency medicine a review. *Can J Anaesth* 50(7): 732-746.
54. Omu A, Al-Harmi J, Vedi H, Mlechkova L, Sayed A, et al. (2008) Al-Ragum N Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait. *Med Princ Pract* 17(3): 227-232.
55. Adewole I, Oladokun A, Okewole A, Omigbodun A, Afolabi A, et al. (2000) Magnesium sulphate for treatment of eclampsia the Nigerian experience. *Afr J Med Med Sci* 29(3-4): 239-241.
56. Shamsuddin L, Nahar K, Nasrin B, Nahar S, Tamanna S, et al. (2005) Use of Parenteral Magnesium Sulphate in Eclampsia and Severe Pre-eclampsia Cases in a Rural set up of Bangladesh. *Bangladesh Med Res Coun Bull* 31(2): 75-82.
57. Langer A, Villar J, Tell K, Kim T, Kennedy S (2008) Reducing eclampsia-related deaths—a call to action. *Lancet* 371(9614): 705-706.
58. Zuspan FP (1978) Problems encountered in the treatment of pregnancy-induced hypertension. A point of view. *Am J Obstet Gynecol* 131(6): 591-597.
59. Lu JF, Nightingale CH (2000) Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. *Clin Pharmacokinet* 38(4): 305-314.
60. Tukur J (2009) The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. *Ann Afr Med* 8(2): 76-80.
61. Mizutani S, Wright J, Kobayashi H (2011) A new approach regarding the treatment of preeclampsia and preterm labor. *Life Sci* 88(1-2): 17-23.
62. Tannirandom Y (2005) Is magnesium sulfate for prevention or only therapeutic in preeclampsia? *J Med Assoc Thai* 88(7): 1003-1010.
63. Muganyizi PS, Shagdara MS (2011) Predictors of extra care among magnesium sulphate treated eclamptic patients at Muhimbili National Hospital, Tanzania. *BMC Pregnancy Childbirth* 11: 41.
64. Kassie GM, Negussie D, Ahmed JH (2014) Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia. *Pharm Pract* 12(2): 400.
65. Chaudhary P (2005) Eclampsia: before and after magnesium sulphate. *Journal of Nepal Medical Association.* 44(160).
66. Abdul MA IU, Tukur J, Yusuf MD (2013) Low dose Magnesium sulphate in the management of eclamptic fits: Randomised controlled trial. *Arch Gynecol Obstet* 287(1): 43-46.
67. Begum R, Begum A, Johanson R, Ali MN, Akhter S (2011) A low dose ('Dhaka') magnesium sulphate regime for eclampsia. *Acta Obstet Gynecol Scand* 80(11): 998-1002.
68. Ekele B, Ahmed Y (2004) Magnesium sulfate regimens for eclampsia. *International Journal of Gynecology & Obstetrics.* 87(2): 149-50.
69. Ekele B, Badung S (2005) Is serum magnesium estimate necessary in patients with eclampsia on magnesium sulphate? *Afr J Reprod Health* 9(1): 128-132.

70. Mundle S, Regi A, Easterling T, Biswas B, Bracken H, et al. (2012) Treatment approaches for preeclampsia in low-resource settings: A randomized trial of the Springfusor pump for delivery of magnesium sulfate. *Pregnancy Hypertens* 2(1): 32-38.
71. Vigil-De Gracia P (2009) Maternal deaths due to eclampsia and HELLP syndrome. *Int J Gynaecol Obstet* 104(2): 90-94.
72. Khan I (2010) Magnesium Sulfate Versus Diazepam Infusion in Eclampsia. *Annals of King Edward Medical University, Pakistan*, 15(3).
73. Ola RE, Odeneye O, Abudu OO (2005) Eclampsia: A Randomized Double Blind Trial of Magnesium Sulphate and Diazepam in Lagos, Nigeria. *Trop J Obstet Gynaeco* 21(2): 143-147.

